HALO
Halozyme Therapeutics, Inc.
Price Chart
Latest Quote
$71.47
+1.85 (+2.66%)
Current Price
| Previous Close | $69.62 |
| Open | $70.12 |
| Day High | $71.77 |
| Day Low | $69.72 |
| Volume | 586,135 |
Stock Information
| Shares Outstanding | 118.61M |
| Total Debt | $2.18B |
| Cash Equivalents | $318.62M |
| Revenue | $1.51B |
| Net Income | $348.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.48B |
| P/E Ratio | 25.08 |
| EPS (TTM) | $2.85 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.12B |
| Sales | $1.51B |
| Income | $348.84M |
| Book/sh | $1.85 |
| Cash/sh | $2.69 |
| Employees | 423 |
Financial Ratios
| Quick Ratio | 2.14 |
| Current Ratio | 2.76 |
| Debt/Eq | 991.21 |
| EPS Growth TTM | 27.10% |
Returns & Margins
| ROA | 22.06% |
| ROE | 99.40% |
| Gross Margin | 76.67% |
| Operating Margin | 48.98% |
| Profit Margin | 23.13% |
Ownership
| Insider Ownership | 1.07% |
| Institutional Ownership | 107.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 7.22 |
| P/S | 5.62 |
| P/B | 38.57 |
Analyst Data
| Recommendation | buy |
| Target Price | $83.90 |
Technical Indicators
| SMA20 | $69.59 |
| SMA50 | $68.02 |
| SMA200 | $69.10 |
| RSI | 56.22 |
| ATR | 2.0607 |
| Shares Float | 117.21M |
| Short Float | 14.88% |
| Short Ratio | 7.52 |
| Volatility | 0.87 |
| Rel Volume | 0.33 |
Performance History
| Week | +2.63% |
| Month | +4.61% |
| Quarter | +15.20% |
| 6 Months | +6.12% |
| YTD | +1.65% |
| Year | +35.36% |
| 3 Years | +104.32% |
| 5 Years | +65.82% |
| 10 Years | +746.80% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $71.47 | 586,150 |
| 2026-06-23 | $69.62 | 2,716,100 |
| 2026-06-22 | $68.99 | 1,054,300 |
| 2026-06-18 | $68.55 | 3,654,000 |
| 2026-06-17 | $68.57 | 1,566,600 |
| 2026-06-16 | $69.64 | 1,950,000 |
| 2026-06-15 | $71.28 | 1,815,500 |
| 2026-06-12 | $69.50 | 1,042,000 |
| 2026-06-11 | $70.73 | 1,344,200 |
| 2026-06-10 | $70.50 | 1,947,500 |
| 2026-06-09 | $71.48 | 1,317,700 |
| 2026-06-08 | $70.73 | 1,497,600 |
| 2026-06-05 | $71.53 | 1,144,500 |
| 2026-06-04 | $71.60 | 2,254,200 |
| 2026-06-03 | $69.82 | 2,144,800 |
| 2026-06-02 | $66.28 | 1,741,000 |
| 2026-06-01 | $68.14 | 2,387,400 |
| 2026-05-29 | $66.54 | 1,917,500 |
| 2026-05-28 | $68.18 | 1,199,000 |
| 2026-05-27 | $68.65 | 2,042,900 |
| 2026-05-26 | $68.72 | 2,031,500 |
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
đ° Latest News
2 Profitable Stocks Worth Your Attention and 1 We Question
StockStory âĸ 2026-06-18T12:37:28Z
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-10T15:30:07Z
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story
Simply Wall St. âĸ 2026-06-04T13:15:48Z
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
StockStory âĸ 2026-06-04T00:15:33Z
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
Investing.com âĸ 2026-05-28T20:27:17ZIs MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Zacks âĸ 2026-05-28T13:20:00Z
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Zacks âĸ 2026-05-27T12:48:00Z
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Zacks âĸ 2026-05-26T13:29:00Z
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns
Simply Wall St. âĸ 2026-05-26T05:07:12Z
Halozyme Therapeuticsâs Q1 Earnings Call: Our Top 5 Analyst Questions
StockStory âĸ 2026-05-19T23:40:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $217,385,000 | $149,154,000 | $181,278,000 | $132,811,000 |
| Cost Of Revenue | $228,774,000 | $159,417,000 | $192,361,000 | $139,304,000 |
| Total Revenue | $1,396,611,000 | $1,015,324,000 | $829,253,000 | $660,116,000 |
| Operating Revenue | $1,396,611,000 | $1,015,324,000 | $829,253,000 | $660,116,000 |
| Expenses | ||||
| Interest Expense | $18,126,000 | $18,095,000 | $18,762,000 | $16,947,000 |
| Total Expenses | $594,018,000 | $463,849,000 | $491,679,000 | $392,585,000 |
| Other Income Expense | $-317,592,000 | $23,752,000 | $29,517,000 | $-1,666,000 |
| Net Non Operating Interest Income Expense | $-18,126,000 | $-18,095,000 | $-18,762,000 | $-16,947,000 |
| Interest Expense Non Operating | $18,126,000 | $18,095,000 | $18,762,000 | $16,947,000 |
| Operating Expense | $365,244,000 | $304,432,000 | $299,318,000 | $253,281,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Net Interest Income | $-18,126,000 | $-18,095,000 | $-18,762,000 | $-16,947,000 |
| Normalized Income | $532,438,690 | $425,158,281 | $257,723,602 | $203,481,792 |
| Net Income From Continuing And Discontinued Operation | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Total Operating Income As Reported | $469,006,000 | $551,475,000 | $337,574,000 | $267,531,000 |
| Net Income Common Stockholders | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Net Income | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Net Income Including Noncontrolling Interests | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Net Income Continuous Operations | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Pretax Income | $466,875,000 | $557,132,000 | $348,329,000 | $248,918,000 |
| Special Income Charges | $-339,064,000 | $0 | $13,200,000 | $-2,712,000 |
| Operating Income | $802,593,000 | $551,475,000 | $337,574,000 | $267,531,000 |
| Depreciation Amortization Depletion Income Statement | $76,662,000 | $71,049,000 | $73,773,000 | $43,148,000 |
| Depreciation And Amortization In Income Statement | $76,662,000 | $71,049,000 | $73,773,000 | $43,148,000 |
| Amortization Of Intangibles Income Statement | $76,662,000 | $71,049,000 | $73,773,000 | $43,148,000 |
| Gross Profit | $1,167,837,000 | $855,907,000 | $636,892,000 | $520,812,000 |
| Per Share | ||||
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 |
| Basic EPS | $2.64 | $3.50 | $2.13 | $1.48 |
| Other | ||||
| Tax Effect Of Unusual Items | $-102,042,310 | $4,819,281 | $5,646,602 | $-313,208 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $890,644,000 | $632,787,000 | $422,430,000 | $317,172,000 |
| Total Unusual Items | $-317,592,000 | $23,752,000 | $29,517,000 | $-1,666,000 |
| Total Unusual Items Excluding Goodwill | $-317,592,000 | $23,752,000 | $29,517,000 | $-1,666,000 |
| Reconciled Depreciation | $88,051,000 | $81,312,000 | $84,856,000 | $49,641,000 |
| EBITDA (Bullshit earnings) | $573,052,000 | $656,539,000 | $451,947,000 | $315,506,000 |
| EBIT | $485,001,000 | $575,227,000 | $367,091,000 | $265,865,000 |
| Diluted Average Shares | $123,904,000 | $129,424,000 | $134,197,000 | $140,608,000 |
| Basic Average Shares | $119,840,000 | $126,827,000 | $131,927,000 | $136,844,000 |
| Diluted NI Availto Com Stockholders | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Tax Provision | $149,986,000 | $113,041,000 | $66,735,000 | $46,789,000 |
| Other Special Charges | $5,477,000 | - | - | $2,712,000 |
| Impairment Of Capital Assets | $48,700,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $284,887,000 | $0 | $-13,200,000 | $0 |
| Gain On Sale Of Security | $21,472,000 | $23,752,000 | $16,317,000 | $1,046,000 |
| Amortization | $76,662,000 | $71,049,000 | $73,773,000 | $43,148,000 |
| Research And Development | $81,490,000 | $79,048,000 | $76,363,000 | $66,607,000 |
| Selling General And Administration | $207,092,000 | $154,335,000 | $149,182,000 | $143,526,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,513,013,000 | $-454,830,000 | $-805,892,000 | $-785,903,000 |
| Total Assets | $2,525,323,000 | $2,063,477,000 | $1,733,270,000 | $1,841,511,000 |
| Other Non Current Assets | $56,152,000 | $80,596,000 | $17,816,000 | $26,801,000 |
| Non Current Deferred Assets | $0 | $3,855,000 | $4,386,000 | $44,426,000 |
| Non Current Deferred Taxes Assets | $0 | $3,855,000 | $4,386,000 | $44,426,000 |
| Goodwill And Other Intangible Assets | $1,561,827,000 | $818,651,000 | $889,700,000 | $955,701,000 |
| Other Intangible Assets | $981,467,000 | $401,830,000 | $472,879,000 | $546,652,000 |
| Current Assets | $825,207,000 | $1,085,340,000 | $746,424,000 | $739,013,000 |
| Other Current Assets | $64,639,000 | $38,951,000 | $48,613,000 | $45,024,000 |
| Inventory | $176,475,000 | $141,860,000 | $127,601,000 | $100,123,000 |
| Receivables | $441,273,000 | $308,455,000 | $234,210,000 | $231,072,000 |
| Receivables Adjustments Allowances | $-9,606,000 | $-8,737,000 | $-6,747,000 | $-1,914,000 |
| Other Receivables | $16,612,000 | $20,251,000 | $956,000 | $44,102,000 |
| Accounts Receivable | $434,267,000 | $296,941,000 | $240,001,000 | $188,884,000 |
| Cash Cash Equivalents And Short Term Investments | $142,820,000 | $596,074,000 | $336,000,000 | $362,794,000 |
| Cash And Cash Equivalents | $133,820,000 | $115,850,000 | $118,370,000 | $234,195,000 |
| Allowance For Doubtful Accounts Receivable | - | - | $-6,747,000 | $-1,914,000 |
| Gross Accounts Receivable | - | - | $240,001,000 | $188,884,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $2,008,810,000 | $1,389,948,000 | $1,380,878,000 | $1,271,905,000 |
| Total Debt | $2,142,630,000 | $1,505,798,000 | $1,499,248,000 | $1,506,100,000 |
| Long Term Debt And Capital Lease Obligation | $2,142,630,000 | $1,505,798,000 | $1,499,248,000 | $1,492,766,000 |
| Long Term Debt | $2,142,630,000 | $1,505,798,000 | $1,499,248,000 | $1,492,766,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $13,334,000 |
| Current Debt | - | - | - | $13,334,000 |
| Other Current Borrowings | - | - | - | $13,334,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,476,509,000 | $1,699,656,000 | $1,649,462,000 | $1,671,713,000 |
| Total Non Current Liabilities Net Minority Interest | $2,299,417,000 | $1,560,556,000 | $1,536,968,000 | $1,540,924,000 |
| Other Non Current Liabilities | $113,863,000 | $54,758,000 | $37,720,000 | $48,158,000 |
| Non Current Deferred Liabilities | $42,924,000 | $0 | - | $2,253,000 |
| Non Current Deferred Taxes Liabilities | $42,924,000 | $0 | - | - |
| Current Liabilities | $177,092,000 | $139,100,000 | $112,494,000 | $130,789,000 |
| Payables And Accrued Expenses | $177,092,000 | $139,100,000 | $112,494,000 | $117,455,000 |
| Payables | $20,899,000 | $10,249,000 | $11,816,000 | $17,693,000 |
| Accounts Payable | $20,899,000 | $10,249,000 | $11,816,000 | $17,693,000 |
| Current Deferred Liabilities | - | - | - | $3,246,000 |
| Equity | ||||
| Common Stock Equity | $48,814,000 | $363,821,000 | $83,808,000 | $169,798,000 |
| Total Equity Gross Minority Interest | $48,814,000 | $363,821,000 | $83,808,000 | $169,798,000 |
| Stockholders Equity | $48,814,000 | $363,821,000 | $83,808,000 | $169,798,000 |
| Gains Losses Not Affecting Retained Earnings | $-18,092,000 | $3,829,000 | $-9,278,000 | $-922,000 |
| Other Equity Adjustments | $-18,092,000 | $3,829,000 | $-9,278,000 | $-922,000 |
| Retained Earnings | $54,786,000 | $359,869,000 | $90,550,000 | $143,217,000 |
| Other | ||||
| Ordinary Shares Number | $117,782,000 | $123,138,000 | $126,770,000 | $135,154,000 |
| Share Issued | $117,782,000 | $123,138,000 | $126,770,000 | $135,154,000 |
| Tangible Book Value | $-1,513,013,000 | $-454,830,000 | $-805,892,000 | $-785,903,000 |
| Invested Capital | $2,191,444,000 | $1,869,619,000 | $1,583,056,000 | $1,675,898,000 |
| Working Capital | $648,115,000 | $946,240,000 | $633,930,000 | $608,224,000 |
| Total Capitalization | $2,191,444,000 | $1,869,619,000 | $1,583,056,000 | $1,662,564,000 |
| Additional Paid In Capital | $12,002,000 | $0 | $2,409,000 | $27,368,000 |
| Capital Stock | $118,000 | $123,000 | $127,000 | $135,000 |
| Common Stock | $118,000 | $123,000 | $127,000 | $135,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $156,193,000 | $128,851,000 | $100,678,000 | $99,762,000 |
| Goodwill | $580,360,000 | $416,821,000 | $416,821,000 | $409,049,000 |
| Net PPE | $82,137,000 | $75,035,000 | $74,944,000 | $75,570,000 |
| Accumulated Depreciation | $-33,159,000 | $-25,429,000 | $-19,661,000 | $-14,756,000 |
| Gross PPE | $115,296,000 | $100,464,000 | $94,605,000 | $90,326,000 |
| Leases | $7,521,000 | $7,012,000 | $6,987,000 | $6,729,000 |
| Other Properties | $97,863,000 | $83,742,000 | $77,896,000 | $75,742,000 |
| Machinery Furniture Equipment | $9,912,000 | $9,710,000 | $9,722,000 | $7,855,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $9,000,000 | $480,224,000 | $217,630,000 | $128,599,000 |
| Finished Goods | - | - | $69,930,000 | $45,970,000 |
| Work In Process | - | - | $34,025,000 | $40,361,000 |
| Raw Materials | - | - | $23,646,000 | $13,792,000 |
| Non Current Deferred Revenue | - | - | - | $2,253,000 |
| Current Deferred Revenue | - | - | - | $3,246,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $356,817,000 | $468,368,000 | $373,277,000 | $235,300,000 |
| Operating Activities | ||||
| Operating Cash Flow | $651,558,000 | $479,064,000 | $388,571,000 | $240,110,000 |
| Cash Flow From Continuing Operating Activities | $651,558,000 | $479,064,000 | $388,571,000 | $240,110,000 |
| Operating Gains Losses | $2,450,000 | $1,522,000 | $611,000 | $1,856,000 |
| Investing Activities | ||||
| Capital Expenditure | $-294,741,000 | $-10,696,000 | $-15,294,000 | $-4,810,000 |
| Investing Cash Flow | $-545,813,000 | $-262,723,000 | $-96,909,000 | $-487,005,000 |
| Cash Flow From Continuing Investing Activities | $-545,813,000 | $-262,723,000 | $-96,909,000 | $-487,005,000 |
| Net Other Investing Changes | - | - | - | $26,006,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-342,372,000 | $-250,000,000 | $-402,383,000 | $-200,002,000 |
| Financing Cash Flow | $-85,174,000 | $-218,861,000 | $-407,987,000 | $362,371,000 |
| Cash Flow From Continuing Financing Activities | $-85,174,000 | $-218,861,000 | $-407,987,000 | $362,371,000 |
| Net Other Financing Charges | $-215,763,000 | - | - | $-76,224,000 |
| Net Common Stock Issuance | $-342,372,000 | $-250,000,000 | $-402,383,000 | $-200,002,000 |
| Other | ||||
| Repayment Of Debt | $-1,018,868,000 | $0 | $-13,483,000 | $-447,453,000 |
| Issuance Of Debt | $1,470,000,000 | $0 | $0 | $1,072,000,000 |
| Interest Paid Supplemental Data | $11,429,000 | $10,565,000 | $11,410,000 | $6,107,000 |
| Income Tax Paid Supplemental Data | $134,641,000 | $80,618,000 | $31,756,000 | $16,224,000 |
| End Cash Position | $136,421,000 | $115,850,000 | $118,370,000 | $234,695,000 |
| Beginning Cash Position | $115,850,000 | $118,370,000 | $234,695,000 | $119,219,000 |
| Changes In Cash | $20,571,000 | $-2,520,000 | $-116,325,000 | $115,476,000 |
| Proceeds From Stock Option Exercised | $21,829,000 | $31,139,000 | $7,879,000 | $14,050,000 |
| Common Stock Payments | $-342,372,000 | $-250,000,000 | $-402,383,000 | $-200,002,000 |
| Net Issuance Payments Of Debt | $451,132,000 | $0 | $-13,483,000 | $624,547,000 |
| Net Long Term Debt Issuance | $451,132,000 | $0 | $-13,483,000 | $624,547,000 |
| Long Term Debt Payments | $-1,018,868,000 | $0 | $-13,483,000 | $-447,453,000 |
| Long Term Debt Issuance | $1,470,000,000 | $0 | $0 | $1,072,000,000 |
| Net Investment Purchase And Sale | $474,893,000 | $-252,027,000 | $-81,615,000 | $490,919,000 |
| Sale Of Investment | $722,248,000 | $395,574,000 | $211,296,000 | $746,127,000 |
| Purchase Of Investment | $-247,355,000 | $-647,601,000 | $-292,911,000 | $-255,208,000 |
| Net Business Purchase And Sale | $-725,965,000 | $0 | $0 | $-999,120,000 |
| Purchase Of Business | $-725,965,000 | $0 | $0 | $-999,120,000 |
| Net Intangibles Purchase And Sale | $-287,771,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-287,771,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-6,970,000 | $-10,696,000 | $-15,294,000 | $-4,810,000 |
| Purchase Of PPE | $-6,970,000 | $-10,696,000 | $-15,294,000 | $-4,810,000 |
| Change In Working Capital | $-152,256,000 | $-89,277,000 | $-38,671,000 | $-85,951,000 |
| Change In Payables And Accrued Expense | $6,211,000 | $46,993,000 | $-12,546,000 | $24,535,000 |
| Change In Prepaid Assets | $-32,958,000 | $5,356,000 | $4,098,000 | $-9,064,000 |
| Change In Inventory | $2,554,000 | $-67,381,000 | $-26,884,000 | $-17,481,000 |
| Change In Receivables | $-128,063,000 | $-74,245,000 | $-3,339,000 | $-83,941,000 |
| Changes In Account Receivables | $-128,063,000 | $-74,245,000 | $-3,339,000 | $-83,941,000 |
| Other Non Cash Items | $298,821,000 | $8,417,000 | $-4,626,000 | $6,927,000 |
| Stock Based Compensation | $51,565,000 | $43,385,000 | $36,620,000 | $24,397,000 |
| Asset Impairment Charge | $48,700,000 | $0 | $0 | $0 |
| Amortization Of Securities | $-3,296,000 | $-10,918,000 | $-6,319,000 | $1,106,000 |
| Deferred Tax | $634,000 | $532,000 | $34,506,000 | $40,005,000 |
| Deferred Income Tax | $634,000 | $532,000 | $34,506,000 | $40,005,000 |
| Depreciation Amortization Depletion | $88,051,000 | $81,312,000 | $84,856,000 | $49,641,000 |
| Depreciation And Amortization | $88,051,000 | $81,312,000 | $84,856,000 | $49,641,000 |
| Amortization Cash Flow | $76,662,000 | $71,049,000 | $73,773,000 | $43,148,000 |
| Amortization Of Intangibles | $76,662,000 | $71,049,000 | $73,773,000 | $43,148,000 |
| Depreciation | $11,389,000 | $10,263,000 | $11,083,000 | $6,493,000 |
| Gain Loss On Investment Securities | $-171,000 | $-7,000 | - | $1,727,000 |
| Gain Loss On Sale Of PPE | $2,621,000 | $1,529,000 | $611,000 | $129,000 |
| Net Income From Continuing Operations | $316,889,000 | $444,091,000 | $281,594,000 | $202,129,000 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-17